Experimental Hematology
Volume 34, Issue 10 , Pages 1360-1376 , October 2006

Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation

  • Amy D. Hartman

      Affiliations

    • Walther Cancer Institute, Indianapolis, Ind., USA
    • ,
  • Annique Wilson-Weekes

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Attaya Suvannasankha

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Gem S. Burgess

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Carissa A. Phillips

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Katie J. Hincher

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • Larry D. Cripe

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • ,
  • H. Scott Boswell

      Affiliations

    • Walther Cancer Institute, Indianapolis, Ind., USA
    • Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind., USA
    • Veterans Affairs Medical Center, Indianapolis, Ind., USA
    • Corresponding Author InformationOffprint requests to: H. Scott Boswell, M.D., Division of Hematology/Oncology, Indiana University Medical Center, Room 202, R4 Building, 1044 W. Walnut Street, Indianapolis, IN 46202

Received 15 February 2006 ,Revised 18 May 2006 ,Accepted 30 May 2006.

References 

  1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2333
  2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting- Airlie House, Virginia, November, 1997. J Clin Oncol. 1999;17:3835–3849
  3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  4. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL group. Blood. 1999;94:1192–1200
  5. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM. Acute myeloid leukemia. Hematology 2002. American Society of Hematology education program book. Available at: http://www.asheducationbook.org/cgi/content/full/2002/1/73.
  6. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–3329
  7. LeGrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91:4480–4488
  8. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 1999;94:1046–1056
  9. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/p-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a SWOG study. Blood. 1999;94:1086–1099
  10. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000;95:3929–3938
  11. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998;92:3090–3097
  12. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of Flt3 and N-ras mutations in acute myeloid leukemia. Blood. 1999;93:3074–3080
  13. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) add important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759
  14. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901–1908
  15. Cripe LD, Gelfanov VM, Smith EA, et al. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. Leukemia. 2002;16:799–812
  16. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. Flt3 signaling in hematopoietic cells involves cbl, shc, and unknown p115 as prominent tyrosine phosphorylated substrates. Leukemia. 1998;12:301–310
  17. Odero MD, Zeleznik-Le N, Chinwalla V, Rowley JD. Cytogenetic and molecular analysis of the acute monocytic leukemia cell line, THP-1, exhibiting t(9;11) (11q23) with MLL-AF9 translocation. Genes Chromosomes Cancer. 2000;29:333–338
  18. Kevin WH, Yee AM, O'Farrell BD, Smolich JM, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 2002;100:2941–2949
  19. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov. 2003;2:554–565
  20. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911–1918
  21. Abu-Dubier FM, Goodeve AC, Wilson A, et al. Identification of novel Flt3 Asp 835 mutations in adult acute myeloid leukemia. Br J Haematol. 2001;113:983–988
  22. Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood. 2005;105:2952–2954
  23. Burgess GS, Williamson EA, Cripe LD, et al. Regulation of the c-jun gene in P210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998;92:2450–2460
  24. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41–47
  25. Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103:267–274
  26. Girardin SE, Yaniv M. A direct interaction between JNK1 and CrkII is critical for Rac1-induced JNK activation. EMBO J. 2001;20:3437–3446
  27. Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. 2005;106:3423–3431
  28. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Ann Rev Cell Dev Biol. 2003;19:91–1118
  29. Adler V, Yizi Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J. 1999;18:1321–1334
  30. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981;35:269–332
  31. Libura M, Asnafi V, Tu A, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood. 2003;102:2198–2204
  32. Morrow CS, Goldsmith ME, Cowan KH. Regulation of human glutathione-S-transferase gene transcription: influence of 5′ flanking sequences and trans activating factors which recognize AP-1 binding sites. Gene. 1990;88:215–225
  33. Dosil M, Wang S, Lemischka IR. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 1993;13:6572–6585
  34. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem. 1999;274:32662–32666
  35. Grossman AH, Kolibaba KS, Willis SG, et al. Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl. FEBS Lett. 2004;577:555–562
  36. Sattler M, Salgia R. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia. 1998;12:637–644
  37. Gelkop S, Babichev Y, Isakov N. T cell activation induces direct binding of the Crk adapter protein to the regulatory subunit of phosphatidylinositol 3-kinase (p85) via a complex mechanism involving the Cbl protein. J Biol Chem. 2001;276:36174–36182
  38. Scheijen B, Ngo HT, Kang H, Griffin JD. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene. 2004;23:3338–3349
  39. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885–3891
  40. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences in comparison to Flt3 ITD mutations. Blood. 2005;106:265–273
  41. Robinson LJ, Xue J, Corey SJ. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol. 2005;33:469–479
  42. Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005;105:1759–1767
  43. Raitano AB, Halpern JR, Hambruch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates jun kinase and requires jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746–11750
  44. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 1991;354:494–496
  45. Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112:181–192
  46. Angel P, Hattori K, Smeal T, Karin M. The c-jun protooncogene is positively autoregulated by its product, c-jun/AP-1. Cell. 1988;55:875–885
  47. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-jun is p53-dependent. Genes Dev. 1999;13:607–619
  48. Shaulian E, Schreiber M, Piu F, Beecher M, Wagner EF, Karin M. The mammalian UV response: c-jun induction is required for exit from p53-imposed growth arrest. Cell. 2000;103:897–907
  49. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005;37:1289–1295
  50. Bulavin DV, Kovalsky O, Hollander MC, Fornace AJ. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol. 2003;23:3859–3871
  51. Bulavin DV, Phillips C, Nannenga B, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet. 2004;36:343–350
  52. Edlund S, Bu S, Schuster N, et al. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell. 2003;14:529–544
  53. Li Y, Sassano A, Majchrzak B, et al. Role of p38alpha map kinase in type I interferon signaling. J Biol Chem. 2004;279:970–979
  54. Parmar S, Katsoulidis E, Verma A, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem. 2004;279:25345–25352
  55. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118:217–228
  56. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-jun (NH2) terminal kinase in transformed B lymphoblasts. Nat Genet. 2002;32:201–205

PII: S0301-472X(06)00336-5

doi: 10.1016/j.exphem.2006.05.019

Experimental Hematology
Volume 34, Issue 10 , Pages 1360-1376 , October 2006

Article Tools

* Image Usage & Resolution